Loading…
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
Worldwide, many countries have adopted colorectal cancer (CRC) screening programmes, often based on faecal occult blood tests (FOBTs). CRC screening aims to detect advanced neoplasia (AN), which is defined as CRC or advanced adenomas. FOBTs fall into two categories based on detection technique and t...
Saved in:
| Published in: | Cochrane database of systematic reviews 2022-06, Vol.6 (6), p.CD009276-CD009276 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4732-4d169713fa2ddb14fb0ba17db7430bf3c8ca5af13f9dafbd0e19cb072a83724f3 |
|---|---|
| cites | |
| container_end_page | CD009276 |
| container_issue | 6 |
| container_start_page | CD009276 |
| container_title | Cochrane database of systematic reviews |
| container_volume | 6 |
| creator | Grobbee, Esmée J Wisse, Pieter HA Schreuders, Eline H van Roon, Aafke van Dam, Leonie Zauber, Ann G Lansdorp-Vogelaar, Iris Bramer, Wichor Berhane, Sarah Deeks, Jonathan J Steyerberg, Ewout W van Leerdam, Monique E Spaander, Manon Cw Kuipers, Ernst J |
| description | Worldwide, many countries have adopted colorectal cancer (CRC) screening programmes, often based on faecal occult blood tests (FOBTs). CRC screening aims to detect advanced neoplasia (AN), which is defined as CRC or advanced adenomas. FOBTs fall into two categories based on detection technique and the detected blood component: qualitative guaiac-based FOBTs (gFOBTs) and faecal immunochemical tests (FITs), which can be qualitative and quantitative. Screening with gFOBTs reduces CRC-related mortality.
To compare the diagnostic test accuracy of gFOBT and FIT screening for detecting advanced colorectal neoplasia in average-risk individuals.
We searched CENTRAL, MEDLINE, Embase, BIOSIS Citation Index, Science Citation Index Expanded, and Google Scholar. We searched the reference lists and PubMed-related articles of included studies to identify additional studies.
We included prospective and retrospective studies that provided the number of true positives, false positives, false negatives, and true negatives for gFOBTs, FITs, or both, with colonoscopy as reference standard. We excluded case-control studies. We included studies in which all participants underwent both index test and reference standard ("reference standard: all"), and studies in which only participants with a positive index test underwent the reference standard while participants with a negative test were followed for at least one year for development of interval carcinomas ("reference standard: positive"). The target population consisted of asymptomatic, average-risk individuals undergoing CRC screening. The target conditions were CRC and advanced neoplasia (advanced adenomas and CRC combined).
Two review authors independently screened and selected studies for inclusion. In case of disagreement, a third review author made the final decision. We used the Rutter and Gatsonis hierarchical summary receiver operating characteristic model to explore differences between tests and identify potential sources of heterogeneity, and the bivariate hierarchical model to estimate sensitivity and specificity at common thresholds: 10 µg haemoglobin (Hb)/g faeces and 20 µg Hb/g faeces. We performed indirect comparisons of the accuracy of the two tests and direct comparisons when both index tests were evaluated in the same population.
We ran the initial search on 25 June 2019, which yielded 63 studies for inclusion. We ran a top-up search on 14 September 2021, which yielded one potentially eligible study, currently |
| doi_str_mv | 10.1002/14651858.CD009276.pub2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9169237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2674002383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4732-4d169713fa2ddb14fb0ba17db7430bf3c8ca5af13f9dafbd0e19cb072a83724f3</originalsourceid><addsrcrecordid>eNpVUctOwzAQtJAQLYVfqHzkkuJHEicXJFSeEhIXkLhF61drSOJiJ5X4AP4boxYEp9ndGc1odxGaU7KghLBzmpcFrYpqsbwipGaiXGxGyQ7QNBF1ltf8ZYKOY3wlhNeUVkdowouyLFI9RZ-3IzhQmYRoNLZgFLTYKzW2A5at9xoPJg4Rb02IY_wRuK4be6_WpnPf7U5ifcDKtz4YNaShgl6ZgKMKxvSuX2HXY0g2sDJZcPEt9dptnR6hjSfo0CYwp3ucoeeb66flXfbweHu_vHzIVC44y3JNy1pQboFpLWluJZFAhZYi50RarioFBdgkqDVYqYmhtZJEMKi4YLnlM3Sx800H6oxWph8CtM0muA7CR-PBNf-Z3q2bld82dQpmXCSDs71B8O9jWrvpXFSmbaE3fowNK0WeXsIrnqTzv1m_IT-351-GRIuJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2674002383</pqid></control><display><type>article</type><title>Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals</title><source>Alma/SFX Local Collection</source><creator>Grobbee, Esmée J ; Wisse, Pieter HA ; Schreuders, Eline H ; van Roon, Aafke ; van Dam, Leonie ; Zauber, Ann G ; Lansdorp-Vogelaar, Iris ; Bramer, Wichor ; Berhane, Sarah ; Deeks, Jonathan J ; Steyerberg, Ewout W ; van Leerdam, Monique E ; Spaander, Manon Cw ; Kuipers, Ernst J</creator><creatorcontrib>Grobbee, Esmée J ; Wisse, Pieter HA ; Schreuders, Eline H ; van Roon, Aafke ; van Dam, Leonie ; Zauber, Ann G ; Lansdorp-Vogelaar, Iris ; Bramer, Wichor ; Berhane, Sarah ; Deeks, Jonathan J ; Steyerberg, Ewout W ; van Leerdam, Monique E ; Spaander, Manon Cw ; Kuipers, Ernst J</creatorcontrib><description><![CDATA[Worldwide, many countries have adopted colorectal cancer (CRC) screening programmes, often based on faecal occult blood tests (FOBTs). CRC screening aims to detect advanced neoplasia (AN), which is defined as CRC or advanced adenomas. FOBTs fall into two categories based on detection technique and the detected blood component: qualitative guaiac-based FOBTs (gFOBTs) and faecal immunochemical tests (FITs), which can be qualitative and quantitative. Screening with gFOBTs reduces CRC-related mortality.
To compare the diagnostic test accuracy of gFOBT and FIT screening for detecting advanced colorectal neoplasia in average-risk individuals.
We searched CENTRAL, MEDLINE, Embase, BIOSIS Citation Index, Science Citation Index Expanded, and Google Scholar. We searched the reference lists and PubMed-related articles of included studies to identify additional studies.
We included prospective and retrospective studies that provided the number of true positives, false positives, false negatives, and true negatives for gFOBTs, FITs, or both, with colonoscopy as reference standard. We excluded case-control studies. We included studies in which all participants underwent both index test and reference standard ("reference standard: all"), and studies in which only participants with a positive index test underwent the reference standard while participants with a negative test were followed for at least one year for development of interval carcinomas ("reference standard: positive"). The target population consisted of asymptomatic, average-risk individuals undergoing CRC screening. The target conditions were CRC and advanced neoplasia (advanced adenomas and CRC combined).
Two review authors independently screened and selected studies for inclusion. In case of disagreement, a third review author made the final decision. We used the Rutter and Gatsonis hierarchical summary receiver operating characteristic model to explore differences between tests and identify potential sources of heterogeneity, and the bivariate hierarchical model to estimate sensitivity and specificity at common thresholds: 10 µg haemoglobin (Hb)/g faeces and 20 µg Hb/g faeces. We performed indirect comparisons of the accuracy of the two tests and direct comparisons when both index tests were evaluated in the same population.
We ran the initial search on 25 June 2019, which yielded 63 studies for inclusion. We ran a top-up search on 14 September 2021, which yielded one potentially eligible study, currently awaiting classification. We included a total of 33 "reference standard: all" published articles involving 104,640 participants. Six studies evaluated only gFOBTs, 23 studies evaluated only FITs, and four studies included both gFOBTs and FITs. The cut-off for positivity of FITs varied between 2.4 μg and 50 µg Hb/g faeces. For each Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability than gFOBTs for AN (P < 0.001) and CRC (P = 0.004). For the detection of AN, the summary sensitivity of gFOBTs was 15% (95% confidence interval (CI) 12% to 20%), which was significantly lower than FITs at both 10 μg and 20 μg Hb/g cut-offs with summary sensitivities of 33% (95% CI 27% to 40%; P < 0.001) and 26% (95% CI 21% to 31%, P = 0.002), respectively. Results were simulated in a hypothetical cohort of 10,000 screening participants with 1% CRC prevalence and 10% AN prevalence. Out of 1000 participants with AN, gFOBTs missed 850, while FITs missed 670 (10 μg Hb/g cut-off) and 740 (20 μg Hb/g cut-off). No significant differences in summary specificity for AN detection were found between gFOBTs (94%; 95% CI 92% to 96%), and FITs at 10 μg Hb/g cut-off (93%; 95% CI 90% to 95%) and at 20 μg Hb/g cut-off (97%; 95% CI 95% to 98%). So, among 9000 participants without AN, 540 were offered (unnecessary) colonoscopy with gFOBTs compared to 630 (10 μg Hb/g) and 270 (20 μg Hb/g) with FITs. Similarly, for the detection of CRC, the summary sensitivity of gFOBTs, 39% (95% CI 25% to 55%), was significantly lower than FITs at 10 μg and 20 μg Hb/g cut-offs: 76% (95% CI 57% to 88%: P = 0.001) and 65% (95% CI 46% to 80%; P = 0.035), respectively. So, out of 100 participants with CRC, gFOBTs missed 61, and FITs missed 24 (10 μg Hb/g) and 35 (20 μg Hb/g). No significant differences in summary specificity for CRC were found between gFOBTs (94%; 95% CI 91% to 96%), and FITs at the 10 μg Hb/g cut-off (94%; 95% CI 87% to 97%) and 20 μg Hb/g cut-off (96%; 95% CI 91% to 98%). So, out of 9900 participants without CRC, 594 were offered (unnecessary) colonoscopy with gFOBTs versus 594 (10 μg Hb/g) and 396 (20 μg Hb/g) with FITs. In five studies that compared FITs and gFOBTs in the same population, FITs showed a higher discriminative ability for AN than gFOBTs (P = 0.003). We included a total of 30 "reference standard: positive" studies involving 3,664,934 participants. Of these, eight were gFOBT-only studies, 18 were FIT-only studies, and four studies combined both gFOBTs and FITs. The cut-off for positivity of FITs varied between 5 µg to 250 µg Hb/g faeces. For each QUADAS-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability for detecting CRC than gFOBTs (P < 0.001). The summary sensitivity for CRC of gFOBTs, 59% (95% CI 55% to 64%), was significantly lower than FITs at the 10 μg Hb/g cut-off, 89% (95% CI 80% to 95%; P < 0.001) and the 20 μg Hb/g cut-off, 89% (95% CI 85% to 92%; P < 0.001). So, in the hypothetical cohort with 100 participants with CRC, gFOBTs missed 41, while FITs missed 11 (10 μg Hb/g) and 11 (20 μg Hb/g). The summary specificity of gFOBTs was 98% (95% CI 98% to 99%), which was higher than FITs at both 10 μg and 20 μg Hb/g cut-offs: 94% (95% CI 92% to 95%; P < 0.001) and 95% (95% CI 94% to 96%; P < 0.001), respectively. So, out of 9900 participants without CRC, 198 were offered (unnecessary) colonoscopy with gFOBTs compared to 594 (10 μg Hb/g) and 495 (20 μg Hb/g) with FITs. At a specificity of 90% and 95%, FITs had a higher sensitivity than gFOBTs.
FITs are superior to gFOBTs in detecting AN and CRC in average-risk individuals. Specificity of both tests was similar in "reference standard: all" studies, whereas specificity was significantly higher for gFOBTs than FITs in "reference standard: positive" studies. However, at pre-specified specificities, the sensitivity of FITs was significantly higher than gFOBTs.]]></description><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD009276.pub2</identifier><identifier>PMID: 35665911</identifier><language>eng</language><publisher>England: John Wiley & Sons, Ltd</publisher><subject>Adenoma - diagnosis ; Cancer ; Colorectal Neoplasms - diagnosis ; Diagnosis ; Early Detection of Cancer - methods ; Gastroenterology & hepatology ; Guaiac ; Hemoglobins ; Humans ; Neoplastic diseases of the colon ; Neoplastic diseases of the rectum and anus ; Occult Blood ; Prevention and screening of colorectal cancer or polyps ; Prospective Studies ; Retrospective Studies ; Sensitivity and Specificity</subject><ispartof>Cochrane database of systematic reviews, 2022-06, Vol.6 (6), p.CD009276-CD009276</ispartof><rights>Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4732-4d169713fa2ddb14fb0ba17db7430bf3c8ca5af13f9dafbd0e19cb072a83724f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35665911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grobbee, Esmée J</creatorcontrib><creatorcontrib>Wisse, Pieter HA</creatorcontrib><creatorcontrib>Schreuders, Eline H</creatorcontrib><creatorcontrib>van Roon, Aafke</creatorcontrib><creatorcontrib>van Dam, Leonie</creatorcontrib><creatorcontrib>Zauber, Ann G</creatorcontrib><creatorcontrib>Lansdorp-Vogelaar, Iris</creatorcontrib><creatorcontrib>Bramer, Wichor</creatorcontrib><creatorcontrib>Berhane, Sarah</creatorcontrib><creatorcontrib>Deeks, Jonathan J</creatorcontrib><creatorcontrib>Steyerberg, Ewout W</creatorcontrib><creatorcontrib>van Leerdam, Monique E</creatorcontrib><creatorcontrib>Spaander, Manon Cw</creatorcontrib><creatorcontrib>Kuipers, Ernst J</creatorcontrib><title>Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description><![CDATA[Worldwide, many countries have adopted colorectal cancer (CRC) screening programmes, often based on faecal occult blood tests (FOBTs). CRC screening aims to detect advanced neoplasia (AN), which is defined as CRC or advanced adenomas. FOBTs fall into two categories based on detection technique and the detected blood component: qualitative guaiac-based FOBTs (gFOBTs) and faecal immunochemical tests (FITs), which can be qualitative and quantitative. Screening with gFOBTs reduces CRC-related mortality.
To compare the diagnostic test accuracy of gFOBT and FIT screening for detecting advanced colorectal neoplasia in average-risk individuals.
We searched CENTRAL, MEDLINE, Embase, BIOSIS Citation Index, Science Citation Index Expanded, and Google Scholar. We searched the reference lists and PubMed-related articles of included studies to identify additional studies.
We included prospective and retrospective studies that provided the number of true positives, false positives, false negatives, and true negatives for gFOBTs, FITs, or both, with colonoscopy as reference standard. We excluded case-control studies. We included studies in which all participants underwent both index test and reference standard ("reference standard: all"), and studies in which only participants with a positive index test underwent the reference standard while participants with a negative test were followed for at least one year for development of interval carcinomas ("reference standard: positive"). The target population consisted of asymptomatic, average-risk individuals undergoing CRC screening. The target conditions were CRC and advanced neoplasia (advanced adenomas and CRC combined).
Two review authors independently screened and selected studies for inclusion. In case of disagreement, a third review author made the final decision. We used the Rutter and Gatsonis hierarchical summary receiver operating characteristic model to explore differences between tests and identify potential sources of heterogeneity, and the bivariate hierarchical model to estimate sensitivity and specificity at common thresholds: 10 µg haemoglobin (Hb)/g faeces and 20 µg Hb/g faeces. We performed indirect comparisons of the accuracy of the two tests and direct comparisons when both index tests were evaluated in the same population.
We ran the initial search on 25 June 2019, which yielded 63 studies for inclusion. We ran a top-up search on 14 September 2021, which yielded one potentially eligible study, currently awaiting classification. We included a total of 33 "reference standard: all" published articles involving 104,640 participants. Six studies evaluated only gFOBTs, 23 studies evaluated only FITs, and four studies included both gFOBTs and FITs. The cut-off for positivity of FITs varied between 2.4 μg and 50 µg Hb/g faeces. For each Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability than gFOBTs for AN (P < 0.001) and CRC (P = 0.004). For the detection of AN, the summary sensitivity of gFOBTs was 15% (95% confidence interval (CI) 12% to 20%), which was significantly lower than FITs at both 10 μg and 20 μg Hb/g cut-offs with summary sensitivities of 33% (95% CI 27% to 40%; P < 0.001) and 26% (95% CI 21% to 31%, P = 0.002), respectively. Results were simulated in a hypothetical cohort of 10,000 screening participants with 1% CRC prevalence and 10% AN prevalence. Out of 1000 participants with AN, gFOBTs missed 850, while FITs missed 670 (10 μg Hb/g cut-off) and 740 (20 μg Hb/g cut-off). No significant differences in summary specificity for AN detection were found between gFOBTs (94%; 95% CI 92% to 96%), and FITs at 10 μg Hb/g cut-off (93%; 95% CI 90% to 95%) and at 20 μg Hb/g cut-off (97%; 95% CI 95% to 98%). So, among 9000 participants without AN, 540 were offered (unnecessary) colonoscopy with gFOBTs compared to 630 (10 μg Hb/g) and 270 (20 μg Hb/g) with FITs. Similarly, for the detection of CRC, the summary sensitivity of gFOBTs, 39% (95% CI 25% to 55%), was significantly lower than FITs at 10 μg and 20 μg Hb/g cut-offs: 76% (95% CI 57% to 88%: P = 0.001) and 65% (95% CI 46% to 80%; P = 0.035), respectively. So, out of 100 participants with CRC, gFOBTs missed 61, and FITs missed 24 (10 μg Hb/g) and 35 (20 μg Hb/g). No significant differences in summary specificity for CRC were found between gFOBTs (94%; 95% CI 91% to 96%), and FITs at the 10 μg Hb/g cut-off (94%; 95% CI 87% to 97%) and 20 μg Hb/g cut-off (96%; 95% CI 91% to 98%). So, out of 9900 participants without CRC, 594 were offered (unnecessary) colonoscopy with gFOBTs versus 594 (10 μg Hb/g) and 396 (20 μg Hb/g) with FITs. In five studies that compared FITs and gFOBTs in the same population, FITs showed a higher discriminative ability for AN than gFOBTs (P = 0.003). We included a total of 30 "reference standard: positive" studies involving 3,664,934 participants. Of these, eight were gFOBT-only studies, 18 were FIT-only studies, and four studies combined both gFOBTs and FITs. The cut-off for positivity of FITs varied between 5 µg to 250 µg Hb/g faeces. For each QUADAS-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability for detecting CRC than gFOBTs (P < 0.001). The summary sensitivity for CRC of gFOBTs, 59% (95% CI 55% to 64%), was significantly lower than FITs at the 10 μg Hb/g cut-off, 89% (95% CI 80% to 95%; P < 0.001) and the 20 μg Hb/g cut-off, 89% (95% CI 85% to 92%; P < 0.001). So, in the hypothetical cohort with 100 participants with CRC, gFOBTs missed 41, while FITs missed 11 (10 μg Hb/g) and 11 (20 μg Hb/g). The summary specificity of gFOBTs was 98% (95% CI 98% to 99%), which was higher than FITs at both 10 μg and 20 μg Hb/g cut-offs: 94% (95% CI 92% to 95%; P < 0.001) and 95% (95% CI 94% to 96%; P < 0.001), respectively. So, out of 9900 participants without CRC, 198 were offered (unnecessary) colonoscopy with gFOBTs compared to 594 (10 μg Hb/g) and 495 (20 μg Hb/g) with FITs. At a specificity of 90% and 95%, FITs had a higher sensitivity than gFOBTs.
FITs are superior to gFOBTs in detecting AN and CRC in average-risk individuals. Specificity of both tests was similar in "reference standard: all" studies, whereas specificity was significantly higher for gFOBTs than FITs in "reference standard: positive" studies. However, at pre-specified specificities, the sensitivity of FITs was significantly higher than gFOBTs.]]></description><subject>Adenoma - diagnosis</subject><subject>Cancer</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Diagnosis</subject><subject>Early Detection of Cancer - methods</subject><subject>Gastroenterology & hepatology</subject><subject>Guaiac</subject><subject>Hemoglobins</subject><subject>Humans</subject><subject>Neoplastic diseases of the colon</subject><subject>Neoplastic diseases of the rectum and anus</subject><subject>Occult Blood</subject><subject>Prevention and screening of colorectal cancer or polyps</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtJAQLYVfqHzkkuJHEicXJFSeEhIXkLhF61drSOJiJ5X4AP4boxYEp9ndGc1odxGaU7KghLBzmpcFrYpqsbwipGaiXGxGyQ7QNBF1ltf8ZYKOY3wlhNeUVkdowouyLFI9RZ-3IzhQmYRoNLZgFLTYKzW2A5at9xoPJg4Rb02IY_wRuK4be6_WpnPf7U5ifcDKtz4YNaShgl6ZgKMKxvSuX2HXY0g2sDJZcPEt9dptnR6hjSfo0CYwp3ucoeeb66flXfbweHu_vHzIVC44y3JNy1pQboFpLWluJZFAhZYi50RarioFBdgkqDVYqYmhtZJEMKi4YLnlM3Sx800H6oxWph8CtM0muA7CR-PBNf-Z3q2bld82dQpmXCSDs71B8O9jWrvpXFSmbaE3fowNK0WeXsIrnqTzv1m_IT-351-GRIuJ</recordid><startdate>20220606</startdate><enddate>20220606</enddate><creator>Grobbee, Esmée J</creator><creator>Wisse, Pieter HA</creator><creator>Schreuders, Eline H</creator><creator>van Roon, Aafke</creator><creator>van Dam, Leonie</creator><creator>Zauber, Ann G</creator><creator>Lansdorp-Vogelaar, Iris</creator><creator>Bramer, Wichor</creator><creator>Berhane, Sarah</creator><creator>Deeks, Jonathan J</creator><creator>Steyerberg, Ewout W</creator><creator>van Leerdam, Monique E</creator><creator>Spaander, Manon Cw</creator><creator>Kuipers, Ernst J</creator><general>John Wiley & Sons, Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220606</creationdate><title>Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals</title><author>Grobbee, Esmée J ; Wisse, Pieter HA ; Schreuders, Eline H ; van Roon, Aafke ; van Dam, Leonie ; Zauber, Ann G ; Lansdorp-Vogelaar, Iris ; Bramer, Wichor ; Berhane, Sarah ; Deeks, Jonathan J ; Steyerberg, Ewout W ; van Leerdam, Monique E ; Spaander, Manon Cw ; Kuipers, Ernst J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4732-4d169713fa2ddb14fb0ba17db7430bf3c8ca5af13f9dafbd0e19cb072a83724f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenoma - diagnosis</topic><topic>Cancer</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Diagnosis</topic><topic>Early Detection of Cancer - methods</topic><topic>Gastroenterology & hepatology</topic><topic>Guaiac</topic><topic>Hemoglobins</topic><topic>Humans</topic><topic>Neoplastic diseases of the colon</topic><topic>Neoplastic diseases of the rectum and anus</topic><topic>Occult Blood</topic><topic>Prevention and screening of colorectal cancer or polyps</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grobbee, Esmée J</creatorcontrib><creatorcontrib>Wisse, Pieter HA</creatorcontrib><creatorcontrib>Schreuders, Eline H</creatorcontrib><creatorcontrib>van Roon, Aafke</creatorcontrib><creatorcontrib>van Dam, Leonie</creatorcontrib><creatorcontrib>Zauber, Ann G</creatorcontrib><creatorcontrib>Lansdorp-Vogelaar, Iris</creatorcontrib><creatorcontrib>Bramer, Wichor</creatorcontrib><creatorcontrib>Berhane, Sarah</creatorcontrib><creatorcontrib>Deeks, Jonathan J</creatorcontrib><creatorcontrib>Steyerberg, Ewout W</creatorcontrib><creatorcontrib>van Leerdam, Monique E</creatorcontrib><creatorcontrib>Spaander, Manon Cw</creatorcontrib><creatorcontrib>Kuipers, Ernst J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grobbee, Esmée J</au><au>Wisse, Pieter HA</au><au>Schreuders, Eline H</au><au>van Roon, Aafke</au><au>van Dam, Leonie</au><au>Zauber, Ann G</au><au>Lansdorp-Vogelaar, Iris</au><au>Bramer, Wichor</au><au>Berhane, Sarah</au><au>Deeks, Jonathan J</au><au>Steyerberg, Ewout W</au><au>van Leerdam, Monique E</au><au>Spaander, Manon Cw</au><au>Kuipers, Ernst J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2022-06-06</date><risdate>2022</risdate><volume>6</volume><issue>6</issue><spage>CD009276</spage><epage>CD009276</epage><pages>CD009276-CD009276</pages><eissn>1469-493X</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><notes>ObjectType-Undefined-4</notes><abstract><![CDATA[Worldwide, many countries have adopted colorectal cancer (CRC) screening programmes, often based on faecal occult blood tests (FOBTs). CRC screening aims to detect advanced neoplasia (AN), which is defined as CRC or advanced adenomas. FOBTs fall into two categories based on detection technique and the detected blood component: qualitative guaiac-based FOBTs (gFOBTs) and faecal immunochemical tests (FITs), which can be qualitative and quantitative. Screening with gFOBTs reduces CRC-related mortality.
To compare the diagnostic test accuracy of gFOBT and FIT screening for detecting advanced colorectal neoplasia in average-risk individuals.
We searched CENTRAL, MEDLINE, Embase, BIOSIS Citation Index, Science Citation Index Expanded, and Google Scholar. We searched the reference lists and PubMed-related articles of included studies to identify additional studies.
We included prospective and retrospective studies that provided the number of true positives, false positives, false negatives, and true negatives for gFOBTs, FITs, or both, with colonoscopy as reference standard. We excluded case-control studies. We included studies in which all participants underwent both index test and reference standard ("reference standard: all"), and studies in which only participants with a positive index test underwent the reference standard while participants with a negative test were followed for at least one year for development of interval carcinomas ("reference standard: positive"). The target population consisted of asymptomatic, average-risk individuals undergoing CRC screening. The target conditions were CRC and advanced neoplasia (advanced adenomas and CRC combined).
Two review authors independently screened and selected studies for inclusion. In case of disagreement, a third review author made the final decision. We used the Rutter and Gatsonis hierarchical summary receiver operating characteristic model to explore differences between tests and identify potential sources of heterogeneity, and the bivariate hierarchical model to estimate sensitivity and specificity at common thresholds: 10 µg haemoglobin (Hb)/g faeces and 20 µg Hb/g faeces. We performed indirect comparisons of the accuracy of the two tests and direct comparisons when both index tests were evaluated in the same population.
We ran the initial search on 25 June 2019, which yielded 63 studies for inclusion. We ran a top-up search on 14 September 2021, which yielded one potentially eligible study, currently awaiting classification. We included a total of 33 "reference standard: all" published articles involving 104,640 participants. Six studies evaluated only gFOBTs, 23 studies evaluated only FITs, and four studies included both gFOBTs and FITs. The cut-off for positivity of FITs varied between 2.4 μg and 50 µg Hb/g faeces. For each Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability than gFOBTs for AN (P < 0.001) and CRC (P = 0.004). For the detection of AN, the summary sensitivity of gFOBTs was 15% (95% confidence interval (CI) 12% to 20%), which was significantly lower than FITs at both 10 μg and 20 μg Hb/g cut-offs with summary sensitivities of 33% (95% CI 27% to 40%; P < 0.001) and 26% (95% CI 21% to 31%, P = 0.002), respectively. Results were simulated in a hypothetical cohort of 10,000 screening participants with 1% CRC prevalence and 10% AN prevalence. Out of 1000 participants with AN, gFOBTs missed 850, while FITs missed 670 (10 μg Hb/g cut-off) and 740 (20 μg Hb/g cut-off). No significant differences in summary specificity for AN detection were found between gFOBTs (94%; 95% CI 92% to 96%), and FITs at 10 μg Hb/g cut-off (93%; 95% CI 90% to 95%) and at 20 μg Hb/g cut-off (97%; 95% CI 95% to 98%). So, among 9000 participants without AN, 540 were offered (unnecessary) colonoscopy with gFOBTs compared to 630 (10 μg Hb/g) and 270 (20 μg Hb/g) with FITs. Similarly, for the detection of CRC, the summary sensitivity of gFOBTs, 39% (95% CI 25% to 55%), was significantly lower than FITs at 10 μg and 20 μg Hb/g cut-offs: 76% (95% CI 57% to 88%: P = 0.001) and 65% (95% CI 46% to 80%; P = 0.035), respectively. So, out of 100 participants with CRC, gFOBTs missed 61, and FITs missed 24 (10 μg Hb/g) and 35 (20 μg Hb/g). No significant differences in summary specificity for CRC were found between gFOBTs (94%; 95% CI 91% to 96%), and FITs at the 10 μg Hb/g cut-off (94%; 95% CI 87% to 97%) and 20 μg Hb/g cut-off (96%; 95% CI 91% to 98%). So, out of 9900 participants without CRC, 594 were offered (unnecessary) colonoscopy with gFOBTs versus 594 (10 μg Hb/g) and 396 (20 μg Hb/g) with FITs. In five studies that compared FITs and gFOBTs in the same population, FITs showed a higher discriminative ability for AN than gFOBTs (P = 0.003). We included a total of 30 "reference standard: positive" studies involving 3,664,934 participants. Of these, eight were gFOBT-only studies, 18 were FIT-only studies, and four studies combined both gFOBTs and FITs. The cut-off for positivity of FITs varied between 5 µg to 250 µg Hb/g faeces. For each QUADAS-2 domain, we assessed risk of bias as high in less than 20% of studies. The summary curve showed that FITs had a higher discriminative ability for detecting CRC than gFOBTs (P < 0.001). The summary sensitivity for CRC of gFOBTs, 59% (95% CI 55% to 64%), was significantly lower than FITs at the 10 μg Hb/g cut-off, 89% (95% CI 80% to 95%; P < 0.001) and the 20 μg Hb/g cut-off, 89% (95% CI 85% to 92%; P < 0.001). So, in the hypothetical cohort with 100 participants with CRC, gFOBTs missed 41, while FITs missed 11 (10 μg Hb/g) and 11 (20 μg Hb/g). The summary specificity of gFOBTs was 98% (95% CI 98% to 99%), which was higher than FITs at both 10 μg and 20 μg Hb/g cut-offs: 94% (95% CI 92% to 95%; P < 0.001) and 95% (95% CI 94% to 96%; P < 0.001), respectively. So, out of 9900 participants without CRC, 198 were offered (unnecessary) colonoscopy with gFOBTs compared to 594 (10 μg Hb/g) and 495 (20 μg Hb/g) with FITs. At a specificity of 90% and 95%, FITs had a higher sensitivity than gFOBTs.
FITs are superior to gFOBTs in detecting AN and CRC in average-risk individuals. Specificity of both tests was similar in "reference standard: all" studies, whereas specificity was significantly higher for gFOBTs than FITs in "reference standard: positive" studies. However, at pre-specified specificities, the sensitivity of FITs was significantly higher than gFOBTs.]]></abstract><cop>England</cop><pub>John Wiley & Sons, Ltd</pub><pmid>35665911</pmid><doi>10.1002/14651858.CD009276.pub2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1469-493X |
| ispartof | Cochrane database of systematic reviews, 2022-06, Vol.6 (6), p.CD009276-CD009276 |
| issn | 1469-493X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9169237 |
| source | Alma/SFX Local Collection |
| subjects | Adenoma - diagnosis Cancer Colorectal Neoplasms - diagnosis Diagnosis Early Detection of Cancer - methods Gastroenterology & hepatology Guaiac Hemoglobins Humans Neoplastic diseases of the colon Neoplastic diseases of the rectum and anus Occult Blood Prevention and screening of colorectal cancer or polyps Prospective Studies Retrospective Studies Sensitivity and Specificity |
| title | Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T04%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guaiac-based%20faecal%20occult%20blood%20tests%20versus%20faecal%20immunochemical%20tests%20for%20colorectal%20cancer%20screening%20in%20average-risk%20individuals&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Grobbee,%20Esm%C3%A9e%20J&rft.date=2022-06-06&rft.volume=6&rft.issue=6&rft.spage=CD009276&rft.epage=CD009276&rft.pages=CD009276-CD009276&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.CD009276.pub2&rft_dat=%3Cproquest_pubme%3E2674002383%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4732-4d169713fa2ddb14fb0ba17db7430bf3c8ca5af13f9dafbd0e19cb072a83724f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2674002383&rft_id=info:pmid/35665911&rfr_iscdi=true |